See more : Spectra Systems Corporation (SCTQ) Income Statement Analysis – Financial Results
Complete financial analysis of Valerio Therapeutics Société anonyme (ALVIO.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valerio Therapeutics Société anonyme, a leading company in the Biotechnology industry within the Healthcare sector.
- Senco Gold Limited (SENCO.NS) Income Statement Analysis – Financial Results
- Aura FAT Projects Acquisition Corp (AFARU) Income Statement Analysis – Financial Results
- Nikon Corporation (NINOF) Income Statement Analysis – Financial Results
- Techno Electric & Engineering Company Limited (TECHNOE.BO) Income Statement Analysis – Financial Results
- PT Summarecon Agung Tbk (SMRA.JK) Income Statement Analysis – Financial Results
Valerio Therapeutics SA (ALVIO.PA)
About Valerio Therapeutics SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.80M | 1.44M | 4.06M | 1.78M | 4.29M | 6.13M | 9.51M | 4.42M | 3.48M | 22.08M | 1.47M | 4.03M | 3.23M | 22.53M | 7.54M | 8.17M | 3.53M | 459.83K | 0.00 |
| Cost of Revenue | 533.00K | 514.00K | 368.00K | 1.94M | 350.00K | 215.00K | 634.00K | 655.00K | 337.00K | 248.85K | 264.27K | 375.23K | 9.55M | 859.07K | 398.75K | 314.14K | 52.30K | 143.13K | 79.84K |
| Gross Profit | 1.27M | 929.00K | 3.69M | -166.00K | 3.94M | 5.91M | 8.87M | 3.77M | 3.15M | 21.83M | 1.20M | 3.65M | -6.32M | 21.67M | 7.14M | 7.86M | 3.48M | 316.71K | -79.84K |
| Gross Profit Ratio | 70.39% | 64.38% | 90.94% | -9.35% | 91.84% | 96.49% | 93.33% | 85.19% | 90.32% | 98.87% | 81.98% | 90.68% | -195.57% | 96.19% | 94.71% | 96.16% | 98.52% | 68.87% | 0.00% |
| Research & Development | 9.68M | 7.87M | 3.05M | 2.11M | 5.84M | 4.93M | 15.36M | 14.07M | 12.68M | 9.61M | 9.98M | 4.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.61M | 2.64M | 2.34M | 2.42M | 2.96M | 5.72M | 0.00 | 0.00 | 0.00 | 0.00 | 10.71M | 0.00 | 831.67K | 9.18M | 12.70M | 19.30M | 14.43M | 7.94M | 3.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.12M | 6.34M | 6.54M | 6.67M | 0.00 | 4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.61M | 2.64M | 2.34M | 2.42M | 2.96M | 5.72M | 5.12M | 6.34M | 6.54M | 6.67M | 10.71M | 4.58M | 831.67K | 9.18M | 12.70M | 19.30M | 14.43M | 7.94M | 3.38M |
| Other Expenses | 9.27M | 389.00K | -581.00K | 10.01M | -243.00K | 5.43M | -492.00K | -959.00K | -420.00K | 0.00 | 0.00 | 0.00 | 608.59K | 438.82K | 0.00 | 1.81M | 1.33M | 441.19K | 0.00 |
| Operating Expenses | 21.56M | 18.04M | 9.26M | 9.24M | 19.73M | 21.56M | 75.25M | 26.94M | 25.32M | 22.45M | 16.64M | 15.17M | 8.62M | 19.08M | 22.62M | 31.05M | 23.15M | 13.96M | 6.68M |
| Cost & Expenses | 20.85M | 18.56M | 9.63M | 11.19M | 20.08M | 21.77M | 75.88M | 27.59M | 25.66M | 22.70M | 16.90M | 15.54M | 18.17M | 19.94M | 23.01M | 31.37M | 23.20M | 14.10M | 6.75M |
| Interest Income | 28.00K | 16.00K | 16.00K | 1.00K | 19.00K | 346.00K | 626.00K | 1.54M | 1.81M | 3.02M | 281.17K | 98.68K | 44.49K | 6.87K | 15.33K | 137.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 66.00K | 2.19M | 1.70M | 959.00K | 1.04M | 1.04M | 1.12M | 437.00K | 1.21M | 3.16M | 287.26K | 92.97K | 336.82K | 228.79K | 166.90K | 117.41K | 12.92K | 11.88K | 0.00 |
| Depreciation & Amortization | 1.74M | 33.00K | 511.00K | 654.00K | 698.00K | 588.00K | 1.87M | 1.86M | 2.21M | 842.09K | 3.42K | 603.06K | 409.73K | 374.67K | 656.34K | 330.59K | 669.05K | 242.61K | -2.29M |
| EBITDA | -18.44M | -17.04M | -4.90M | 2.34M | -35.66M | -946.00K | -67.56M | -19.79M | -19.51M | -1.34M | -15.19M | -10.85M | -14.43M | 3.33M | -14.76M | -20.85M | -18.05M | -13.02M | -6.64M |
| EBITDA Ratio | -1,024.67% | -1,183.85% | -120.53% | -460.53% | 171.97% | -15.46% | -268.24% | -447.67% | -522.43% | 15.61% | -1,009.06% | -269.40% | -426.37% | 15.58% | -193.19% | -255.02% | -497.71% | -2,913.19% | 0.00% |
| Operating Income | -20.29M | -17.12M | -5.58M | -7.81M | -9.79M | -15.64M | -19.19M | -23.17M | -22.18M | -616.07K | -15.44M | -11.52M | -14.94M | 2.59M | -15.48M | -23.19M | -19.56M | -13.64M | -6.75M |
| Operating Income Ratio | -1,127.11% | -1,186.07% | -137.42% | -439.98% | -228.40% | -255.33% | -201.88% | -523.69% | -636.88% | -2.79% | -1,052.48% | -285.87% | -462.36% | 11.51% | -205.38% | -283.74% | -554.34% | -2,965.95% | 0.00% |
| Total Other Income/Expenses | -39.00K | -2.55M | -1.52M | -348.00K | -26.26M | -691.00K | -489.00K | 1.06M | 413.00K | -4.93M | 116.59K | -32.72K | 316.26K | 216.90K | 95.36K | 1.83M | 1.32M | 473.12K | -921.18K |
| Income Before Tax | -20.33M | -19.27M | -6.66M | 1.85M | -36.05M | -11.16M | -66.87M | -22.11M | -21.76M | -5.55M | -15.32M | -11.55M | -14.62M | 2.81M | -15.38M | -21.36M | -18.25M | -13.17M | -7.68M |
| Income Before Tax Ratio | -1,129.28% | -1,335.62% | -164.06% | 104.00% | -840.81% | -182.13% | -703.49% | -499.68% | -625.01% | -25.13% | -1,044.53% | -286.68% | -452.57% | 12.47% | -204.12% | -261.38% | -517.03% | -2,863.06% | 0.00% |
| Income Tax Expense | 17.00K | 285.00K | 100.00K | 757.00K | -2.32M | -1.76M | -7.80M | 566.00K | -2.35M | 2.15M | 633.43K | 60.25K | 753.11K | 105.00 | 262.26K | 1.15K | 1.13K | 0.00 | 11.62K |
| Net Income | -20.34M | -19.56M | -5.94M | 1.09M | -33.73M | -9.40M | -59.07M | -22.67M | -19.41M | -7.70M | -15.32M | -11.55M | -14.62M | 2.81M | -15.38M | -21.37M | -18.25M | -13.17M | -7.69M |
| Net Income Ratio | -1,130.22% | -1,355.65% | -146.16% | 61.32% | -786.57% | -153.40% | -621.47% | -512.45% | -557.41% | -34.87% | -1,044.53% | -286.68% | -452.57% | 12.47% | -204.12% | -261.39% | -517.06% | -2,863.06% | 0.00% |
| EPS | -0.15 | -0.18 | -0.07 | 0.01 | -0.55 | -0.18 | -1.16 | -0.48 | -0.48 | -0.19 | -0.74 | -0.65 | -0.82 | 0.20 | -1.14 | -1.59 | -1.40 | -1.45 | -0.89 |
| EPS Diluted | -0.15 | -0.18 | -0.07 | 0.01 | -0.55 | -0.18 | -1.16 | -0.48 | -0.48 | -0.19 | -0.74 | -0.65 | -0.82 | 0.19 | -1.14 | -1.59 | -1.40 | -1.45 | -0.75 |
| Weighted Avg Shares Out | 135.63M | 105.75M | 88.21M | 73.15M | 61.38M | 53.62M | 50.95M | 47.32M | 40.77M | 40.81M | 20.82M | 17.88M | 17.78M | 13.96M | 13.49M | 13.46M | 13.01M | 9.06M | 8.66M |
| Weighted Avg Shares Out (Dil) | 135.63M | 105.75M | 88.21M | 75.87M | 61.38M | 53.62M | 51.03M | 47.35M | 40.81M | 40.81M | 20.82M | 17.88M | 17.78M | 14.66M | 13.49M | 13.46M | 13.01M | 9.06M | 10.26M |
Source: https://incomestatements.info
Category: Stock Reports